Reshaping Vision
POSSIBILITIES
what is presbyopia
Presbyopia is the gradual loss of your eye’s ability to focus on near objects. This progressive condition begins to affect most people sometime after the age of 40, impacting more than 1.8 billion people worldwide.
our solution
CSF-1 is our novel formulation of low-dose pilocarpine and a proprietary vehicle without preservatives. Now nearing completion of Phase 3 clinical trials, CSF-1 is designed to provide the optimal balance of efficacy, safety and comfort.
company updates
Apr 23 2022
Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Apr 21 2022
Apr 12 2022
Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Apr 7 2022
Orasis Pharmaceuticals Appoints Teresa (Tes) Ignacio, M.D. as Vice President, Medical Affairs
Mar 15 2022
Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidate
Oct 3 2021
Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan
Apr 26 2021
Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth
Oct 28 2020
Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia
Sept 10 2020
Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia
May 11 2020
Chief executive officer Elad Kedar spoke with the OIS Podcast on his strategy for success in completing a Phase 2b clincal study and how Orasis is now preparing to move into Phase 3 with our product candidate CSF-1. Chairman Jeffry Weinhuff also offers insights into Visionary Ventures’ investment decisions. Listen to the full podcast here.
Jan 28 2020
Chief executive officer, Elad Kedar, spoke with the Bio Report podcast on the potential of CSF-1 to treat presbyopia or age-related farsightedness and the eye drop’s recent positive Phase 2b study results. Listen to the full podcast here.
Nov 14 2019
Following the positive results from our Phase 2b U.S. clinical trial of CSF-1, Orasis CEO Elad Kedar spoke with Healio Ocular Surgery News about the eye drop and its potential as a meaningful treatment for people with presbyopia. Watch the full interview
Oct 10 2019
Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia
May 29 2019
Orasis CEO Elad Kedar was interviewed by Ophthalmology Innovation Summit (OIS) TV about our corrective eye drop for the treatment of presbyopia and progress in our Phase 2b clinical study
Apr 8 2019
CEO Elad Kedar Discusses Our Ongoing Phase 2b Clinical Study of CSF-1 and the Eye Drop’s Treatment Effect with Healio
Mar 27 2019
Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia